Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06663072 · ClinicalTrials.gov registry record · Phase 1
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
A Phase 1 study of Metastatic Pancreatic Neuroendocrine Tumor, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06663072 is a Phase 1 study of Metastatic Pancreatic Neuroendocrine Tumor that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06663072, a Phase 1 study of Metastatic Pancreatic Neuroendocrine Tumor, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG 177Lu-DOTATATE
Study Locations (1)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-12-13 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06663072
The ClinicalTrials.gov registry entry for NCT06663072 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Pancreatic Neuroendocrine Tumor appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT06663072 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06663072 about?
NCT06663072 is a clinical study titled "Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors". This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
What is the current status of trial NCT06663072?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-12-13. Estimated completion is 2026-11.
What conditions does trial NCT06663072 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Neuroendocrine Tumor.
What interventions are being tested in trial NCT06663072?
The interventions under investigation include: Fulvestrant (DRUG), 177Lu-DOTATATE (DRUG).
Who is sponsoring clinical trial NCT06663072?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06663072 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
RECRUITING · Phase 1
-
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.